Provided by Tiger Fintech (Singapore) Pte. Ltd.

Glaukos

103.20
-8.9200-7.96%
Post-market: 103.790.5900+0.57%17:03 EST
Volume:1.38M
Turnover:144.78M
Market Cap:5.83B
PE:-37.20
High:110.22
Open:109.20
Low:102.97
Close:112.12
Loading ...

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

THOMSON REUTERS
·
17 Oct 2024

Glaukos Corp - Phase 3 Trial Supports Nda Submission by End of 2024

THOMSON REUTERS
·
17 Oct 2024

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Business Wire
·
17 Oct 2024

Glaukos Is Maintained at Buy by Truist Securities

Dow Jones
·
14 Oct 2024

Glaukos price target raised to $152 from $145 at Truist

TIPRANKS
·
14 Oct 2024

Truist Raises Price Target on Glaukos to $152 From $145, Maintains Buy Rating

MT Newswires Live
·
14 Oct 2024

Investing in Glaukos (NYSE:GKOS) three years ago would have delivered you a 174% gain

Simply Wall St.
·
09 Oct 2024

Press Release: Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Dow Jones
·
09 Oct 2024

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?

Zacks
·
03 Oct 2024

S&P 500 Futures Drop In Premarket Trading; Fangdd Network Group, Glaukos Lead

Dow Jones
·
02 Oct 2024

Buy Rating on Glaukos: iDose’s Market Potential and Strategic Advantages Outshine Ripple’s RTC-620

TIPRANKS
·
23 Sep 2024

Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Simply Wall St.
·
18 Sep 2024

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Zacks
·
10 Sep 2024

Here’s Why Glaukos (GKOS) Appreciated in Q2

Insider Monkey
·
09 Sep 2024